Category: Joint ventures/collaborations
-
Campaign Seeks More Minorities in Brain Disorder Trials
13 March 2015. A new public service campaign led by former actress and restaurateur B. Smith aims to recruit more minorities in clinical trials for brain disorders, such Alzheimer’s disease, from which Smith suffers. Smith and her husband Dan Gasby are partnering in the campaign with Brain Health Registry, affiliated with University of California in…
-
MedImmune, Joslin Partner on Diabetes Research
10 March 2015. Joslin Diabetes Center in Boston and MedImmune, the biotechnology subsidiary of pharmaceutical company AstraZeneca, are collaborating on research to identify new drugs to treat diabetes. While the partnership calls for MedImmune to fund research conducted at Joslin, financial terms of the deal were not disclosed. Diabetes is a chronic condition where the pancreas…
-
Gates Invests, Supports R&D in RNA Vaccine Maker
6 March 2015. The Bill and Melinda Gates Foundation is making an equity investment and providing a grant to support research at CureVac GmbH, a developer of vaccines and therapies with RNA molecules. The foundation is investing €46 million ($52 million) in CureVac, in Tübingen, Germany, but the amount of the grant supporting research in…
-
Robot for Reaching Children With Autism Demonstrated
4 March 2015. Milo, a humanoid robot designed to engage and build social skills in children with autism spectrum disorder, was shown today at a press conference in Washington, D.C. The demonstration also reported on early research findings that suggest Milo can reach some children with autism to develop their social interactions. Autism spectrum disorder is…
-
Alliance to Build Photonic Mosquito Control Device
3 March 2015. A collaboration between a social enterprise and lighting technology company aims to develop a laser device to control disease-carrying mosquitoes without pesticides. Financial details of the partnership between Global Good and Lighting Science Group, a designer of advanced industrial and residential lighting systems, were not disclosed. Global Good brings together government, business,…
-
Registry to Track Psoriasis Drug Safety
26 February 2015. A new registry of patients with psoriasis will track the safety of a recently approved biologic drug designed to treat that disorder. The Corrona Psoriasis Registry is a joint undertaking of National Psoriasis Foundation and Corrona LLC, a company in Southborough, Massachusetts hosting registries of patients with chronic diseases. Psoriasis is an…
-
RNA Flu Therapy Clinical Trials Complete Enrollment
19 February 2015. Two late-stage clinical trials testing an influenza treatment that disrupts a virus’s genetic replication ability finished recruiting more than 2,000 participants worldwide. The trials are being conducted by MediVector Inc., a drug development company in Boston, for Joint Project Manager Medical Countermeasure Systems, an office in the U.S. Department of Defense developing…
-
Janssen, Foundation to Devise Diabetes Prevention Strategy
12 February 2015. Janssen Research and Development, a division of Johnson & Johnson, and JDRF plan to investigate new ways to diagnose early conditions and prevent the onset of type 1 diabetes. Financial details of the collaboration between Janssen and JDRF, a foundation supporting research on type 1 diabetes, were not disclosed. Type 1 diabetes is…
-
Foundation, Pfizer Collaborate on Alzheimer’s Targets
11 February 2015. Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are joining forces to sponsor research to find new Alzheimer’s disease drug targets. Financial details of the collaboration were not revealed. The foundation and Pfizer plan to invest in project teams of Pfizer and academic scientists to translate academic research into candidates…
-
Genzyme Licensing Gene Therapies from Biotech Start-Up
11 February 2015. Voyager Therapeutics, a designer of gene therapies for central nervous system diseases, is licensing some of its treatments now in development to Genzyme Corp., a biotechnology subsidiary of the drug maker Sanofi. The deal is expected to bring the one year-old spin-off from four university research labs as much as $845 million.…